Pre-Open Stock Movers 05/28: (AMC) (ITRM) (YEXT) Higher; (PRVB) (HPQ) (BIG) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Put Buying Activity in Beyond Meat (BYND) Targets 10% Downside in Shares Through July -Susquehanna
June 1, 2021 2:10 PM EDTSusquehanna options strategist Alison Edwards notes put buying activity in Beyond Meat (NASDAQ: BYND), as an opening investor purchased 3500 Jul 120 Puts for $4.90. This investor opens downside exposure to/protection against a move below $120 (down 10%).
... MorePalantir (PLTR) Trades at High, Up 7.6%
May 28, 2021 9:57 AM EDTPalantir (NYSE: PLTR) Trades at High, Up 7.6%
Veeva Systems (VEEV) PT Raised to $350 at Guggenheim
May 28, 2021 9:53 AM EDTGuggenheim analyst Ken Wong raised the price target on Veeva Systems (NYSE: VEEV) to $350.00 (from $340.00) while maintaining a Buy rating following strong first quarter results.
The analyst commented, "We view the consistency of Veeva's quarterly execution to be every bit as, if... More
AMC Entertainment (AMC) Extends Gain, Up 35%
May 28, 2021 9:32 AM EDTAMC Entertainment (NYSE: AMC) Extends Gain, Up 35%
Provention Bio Inc. (PRVB) PT Lowered to $22.50 at Chardan Capital Markets Following FDA AdComm Vote
May 28, 2021 9:29 AM EDTChardan Capital Markets analyst Gbola Amusa lowered the price target on Provention Bio Inc. (NASDAQ: PRVB) to $22.50 (from $35.00) while maintaining a Buy rating following the FDA Advisory Committee vote.
The analyst commented, "Provention Bio (Buy): Yesterday, the FDA Advisory Committee (EMDAC)... More

